App-Based Mindfulness for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether a mindfulness app can improve the quality of life for people with kidney cancer that has spread. Participants will use the app for 20-30 minutes a day, at least four times a week, for a month. The study seeks individuals receiving immunotherapy for metastatic kidney cancer, who feel anxious about their cancer worsening, and have a smartphone with internet access. As an unphased trial, this study provides a unique opportunity to explore innovative ways to enhance well-being alongside existing treatments.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. However, since the trial involves mindfulness and not a new drug, it's likely you can continue your current treatments.
What prior data suggests that this app-based mindfulness intervention is safe for patients with metastatic kidney cancer?
Research has shown that mindfulness apps are generally easy for people to use. In a previous study with 50 patients who had advanced kidney cancer, 96% completed their check-ins after four weeks, indicating that most people stick with the app without major issues.
Another study on different mindfulness apps found that while some people stopped using them, most continued. This suggests that using a mindfulness app is usually safe and manageable for many. Additionally, there are no reports of serious side effects, making these apps a low-risk way to improve mental well-being.12345Why are researchers excited about this trial?
Unlike standard treatments for kidney cancer, which often involve surgery, chemotherapy, or targeted drug therapies, the app-based mindfulness program offers a completely different approach. This treatment is unique because it uses a digital delivery method, allowing patients to engage in mindfulness exercises conveniently from their smartphones. It aims to improve mental well-being and potentially enhance quality of life. Researchers are excited about this treatment because it provides a non-invasive, low-risk option that can be easily integrated into patients' daily routines, which might help reduce stress and improve overall health outcomes.
What evidence suggests that this app-based mindfulness intervention is effective for improving quality of life in patients with metastatic kidney cancer?
Research has shown that a mindfulness app can improve the quality of life for people with advanced kidney cancer. In one study with 50 patients, 96% completed the program, indicating ease of use and participant satisfaction. Regular app users reported reduced stress and improved quality of life. Another study found that an 8-week mindfulness program improved sleep and reduced stress. These findings suggest that the mindfulness app, which participants in this trial will use for 20-30 minutes daily over 4 weeks, can help patients manage their condition.12467
Who Is on the Research Team?
Sumanta K Pal
Principal Investigator
City of Hope Medical Center
Are You a Good Fit for This Trial?
This trial is for patients with metastatic renal cell carcinoma who haven't practiced meditation regularly in the past year, have a significant fear of cancer progression, and have not been part of mindfulness-based recovery or stress reduction programs within 5 years. Participants must own a smartphone with internet access, be fluent in English, and currently be receiving immunotherapy.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in a mindfulness-based program using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks
Follow-up
Participants are monitored for psychosocial outcomes, quality of life, and fatigue over a 3-month period
What Are the Treatments Tested in This Trial?
Interventions
- App-Based Mindfulness Intervention
Trial Overview
The study tests an app-based mindfulness program to see if it can improve life quality for those with advanced kidney cancer. It involves using the app to engage in mindfulness exercises and completing questionnaires about their experience and feelings.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients participate in a mindfulness-based program by using the Am app for 20-30 minutes every day, a minimum of 4 days each week over 4 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
City of Hope Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Published Research Related to This Trial
Citations
Feasibility and acceptability of a mindfulness app-based ...
In a multinational study with 50 metastatic renal cell carcinoma patients on immunotherapy, a mindfulness app-based intervention demonstrated 96 ...
App-Based Mindfulness Intervention for the Improvement of ...
This trial tests the feasibility of an application (app)-based mindfulness intervention and its effect on improving quality of life in patients with renal ...
Prospective assessment of a smartphone-app based ...
This is the first study to implement an evidence-based, smartphone-accessible psychosocial support tool among mRCC patients.
Feasibility and acceptability of a mindfulness app-based ...
Results: Among 50 patients with mRCC, the feasibility of this intervention was demonstrated; 96% of patients were assessed at week 4, with high ...
App-Based Mindfulness for Kidney Cancer
Participation in an 8-week mindfulness-based stress reduction (MBSR) program significantly improved quality of life, reduced stress symptoms, and enhanced sleep ...
Mobile Mindfulness Intervention for Psychological Distress ...
This randomized clinical trial evaluates the most effective method for delivering a mindfulness program via mobile app to improve depression ...
7.
bmcdigitalhealth.biomedcentral.com
bmcdigitalhealth.biomedcentral.com/articles/10.1186/s44247-025-00155-7Acceptability, engagement, outcomes, and dose–response ...
In a review of mindfulness app RCTs, there was an average attrition rate of 25%, but this rose to 39% in larger samples (greater than 100 ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.